Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2024-04-26 Report Publication Anno…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
Report Publication Announcement Classification · 95% confidence The document is a media release from BB Biotech AG announcing their first-quarter results for 2024. While it contains financial highlights and portfolio data, it explicitly states at the end of the text that 'The interim report as at March 31, 2024, is available under [link]'. This indicates that the current document is a summary announcement (a 'menu') rather than the full interim report (the 'meal'). According to the 'Menu vs Meal' rule, such announcements are classified as Report Publication Announcements (RPA). Q1 2024
2024-04-26 English
EQS-News: BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt
Earnings Release Classification · 100% confidence The document is titled 'BB BIOTECH AG / Schlagwort(e): Zwischenbericht' and contains detailed financial performance metrics for the first quarter (1. Quartal 2024), including Reingewinn (Net Profit), NAV performance, portfolio adjustments, and outlook. The text explicitly mentions the 'Zwischenbericht per 31. März 2024' (Interim Report as of March 31, 2024) and provides a link to the full report. Since this document summarizes and presents the comprehensive financial results for a period shorter than a year (Q1), it fits the definition of an Interim/Quarterly Report. The document length is substantial (12,937 chars), indicating it is the report content itself, not just a brief announcement of publication (RPA/RNS). Q1 2024
2024-04-26 German
Q1 statement / Q1 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at 31.03.2024' and contains comprehensive financial information, including consolidated interim financial statements, explanatory notes, and a report of the statutory auditors. It covers a period shorter than a full fiscal year (Q1 2024). It is not an announcement of a report, but the report itself, containing substantive financial data and analysis. Q1 2024
2024-04-26 English
BB BIOTECH AG: Dr. Thomas von Planta, buy
Director's Dealing Classification · 100% confidence The document explicitly states 'Directors’ Dealings' in the header and details a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' involving Dr. Thomas von Planta, a 'Member of the administrative or supervisory body'. This directly matches the definition for Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2024-03-26 English
Shareholders at BB Biotech AGs AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
AGM Information Classification · 99% confidence The document explicitly mentions 'Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share'. The key terms are 'AGM' (Annual General Meeting), voting results, and dividend approval. This content directly relates to the outcomes of a shareholder meeting. While it mentions dividend approval (DIV) and board changes (MANG), the overarching context is the formal conclusion and results of the Annual General Meeting. Therefore, the most specific and appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or potentially Declaration of Voting Results & Voting Rights Announcements (DVA). Since the text details the approval of all proposals, including the dividend and board elections, DVA is highly relevant, but AGM-R often encompasses the summary release of the meeting's outcomes. Given the strong focus on the AGM event itself, AGM-R is selected as the primary category, as DVA is often reserved for the formal declaration of vote counts.
2024-03-21 English
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
AGM Information Classification · 99% confidence The document explicitly mentions 'BB BIOTECH AG / Key word(s): AGM/EGM/Dividend' and the headline states, 'Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share'. This content directly relates to the outcomes and decisions made during an Annual General Meeting (AGM), including board elections and dividend approval. This aligns perfectly with the definition for AGM Information (AGM-R). Although dividend information is present (DIV), the primary focus and context is the meeting results.
2024-03-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.